Drugs & Targets FDA approves Ojjaara as first and only treatment for myelofibrosis with anemia September 22, 2023Vol.49 No.35
Drugs & Targets FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer September 22, 2023Vol.49 No.35
Drugs & Targets CHMP issues positive opinion on Keytruda in NSCLC indication September 22, 2023Vol.49 No.35
Drugs & Targets CHMP issues positive opinion on Adcetris in Hodgkin lymphoma September 22, 2023Vol.49 No.35
Drugs & Targets FDA approves Akeega for BRCA-positive metastatic castration-resistant prostate cancer September 15, 2023Vol.49 No.34
Drugs & Targets FDA approves new and updated indications for Temodar under Project Renewal September 15, 2023Vol.49 No.34
Drugs & Targets FDA, Flatiron Health renew five-year research collaboration on real-world data September 15, 2023Vol.49 No.34
Drugs & Targets FDA grants accelerated approval to Elrexfio for r/r multiple myeloma September 08, 2023Vol.49 No.33
Drugs & Targets FDA places partial clinical hold for magrolimab studies in AML September 08, 2023Vol.49 No.33
